Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Innoviva, Inc.INVA · Entity 4679 | Chief Financial Officer | August 20, 2026 | August 24, 2026 |
| Inozyme Pharma, Inc.INZY · Entity 77717 | SVP Finance (PFO) | March 24, 2021 | March 25, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Innoviva, Inc.
Report date August 20, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 88,013 |
Reported balance
After 2026-08-20 transaction · row 1
1 source rowRow 1 · 2026-08-20 · Tax withholding · Disposed 558 · Balance 88,013 F1: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants.
Inozyme Pharma, Inc.
Report date March 24, 2021 · Filed March 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.77 · Expires 2031-03-23 | Direct | 13,000 |
Reported balance
After 2021-03-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-24 · Grant · Acquired 13,000 · Balance 13,000 F1: The option was granted on March 24, 2021. The shares underlying the option are scheduled to vest in equal monthly installments through March 24, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on March 24, 2021. The shares underlying the option are scheduled to vest in equal monthly installments through March 24, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2026 Filed Aug 24, 2026 20:15 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 558 | $21.00 | $11,718.00 |
DisclosureSEC source: 0001193125-26-363610 · ownership.xml · nonDerivative · entry 1 Basso Stephen · CIK 0001815707 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,013 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:15 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 559 | $22.24 | $12,432.16 |
DisclosureSEC source: 0001193125-26-236913 · ownership.xml · nonDerivative · entry 2 Basso Stephen · CIK 0001815707 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,571 F2 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Read SEC document |
| May 15, 2026 Filed May 22, 2026 20:15 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 1,123 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-236913 · ownership.xml · nonDerivative · entry 1 Basso Stephen · CIK 0001815707 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,130 F1 · shares: Includes 1,123 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on May 15, 2026. Read SEC document |
| May 04, 2026 Filed May 6, 2026 20:15 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 93,750 | $0.00 Strike: $22.99 | $0.00 |
DisclosureSEC source: 0001193125-26-209005 · ownership.xml · derivative · entry 2 Basso Stephen · CIK 0001815707 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 93,750 shares Expires 2036-05-03 F1 · derivative.exercise_date: The Reporting Person was conditionally granted time-vested restricted stock units ("RSUs") and non-statutory stock options ("Options"). The RSUs and Options were granted subject to stockholder approval of the Issuer's 2026 Equity Incentive Plan at the Issuer's 2026 annual meeting of stockholders on May 4, 2026, as disclosed in the Issuer's Schedule 14A filed with the Securities and Exchange Commission ("SEC") on March 24, 2026. F2 · derivative.exercise_date: Twenty-five percent of each of the RSUs and Options vest on February 20, 2027 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date, with accelerated vesting (i) with respect to the Options, in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan) in which the options are not assumed or replaced, provided that the Reporting Person has not experienced a termination prior to such "change in control," or (ii) with respect to the Options and the RSUs, in the event that the Reporting Person experiences an "involuntary termination" of employment within 24 months following a "change in control" where such awards are assumed or substituted, subject to an effective release of claims. Read SEC document |
| May 04, 2026 Filed May 6, 2026 20:15 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 37,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-209005 · ownership.xml · nonDerivative · entry 1 Basso Stephen · CIK 0001815707 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,007 F1 · shares: The Reporting Person was conditionally granted time-vested restricted stock units ("RSUs") and non-statutory stock options ("Options"). The RSUs and Options were granted subject to stockholder approval of the Issuer's 2026 Equity Incentive Plan at the Issuer's 2026 annual meeting of stockholders on May 4, 2026, as disclosed in the Issuer's Schedule 14A filed with the Securities and Exchange Commission ("SEC") on March 24, 2026. F2 · shares: Twenty-five percent of each of the RSUs and Options vest on February 20, 2027 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date, with accelerated vesting (i) with respect to the Options, in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan) in which the options are not assumed or replaced, provided that the Reporting Person has not experienced a termination prior to such "change in control," or (ii) with respect to the Options and the RSUs, in the event that the Reporting Person experiences an "involuntary termination" of employment within 24 months following a "change in control" where such awards are assumed or substituted, subject to an effective release of claims. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 21:15 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 1,244 | $23.39 | $29,097.16 |
DisclosureSEC source: 0001193125-26-067029 · ownership.xml · nonDerivative · entry 1 Basso Stephen · CIK 0001815707 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,013 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:17 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 237 | $21.16 | $5,014.92 |
DisclosureSEC source: 0001104659-25-115427 · tm2531942-2_4seq1.xml · nonDerivative · entry 2 Basso Stephen · CIK 0001815707 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,257 F2 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Read SEC document |
| November 15, 2025 Filed Nov 24, 2025 21:17 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 604 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-115427 · tm2531942-2_4seq1.xml · nonDerivative · entry 1 Basso Stephen · CIK 0001815707 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,494 F1 · shares: Includes 604 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on November 15, 2025. Read SEC document |
| November 03, 2025 Filed Nov 6, 2025 02:45 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 27,609 | $18.11 | $499,998.99 |
DisclosureSEC source: 0001104659-25-107236 · tm2530357-1_4seq1.xml · nonDerivative · entry 1 Basso Stephen · CIK 0001815707 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,890 F1 · balance_after: The Reporting Person was granted a time-vested restricted stock unit ("RSU"). Twenty-five percent of the shares subject to the RSU vest on November 20, 2026 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date, with accelerated vesting (i) in the event of a "change in control" (as defined in the Issuer's 2012 Equity Incentive Plan) in which the RSU is not assumed or replaced, or (ii) in the event that the Reporting Person experiences an "involuntary termination" of employment within 24 months following a "change in control," subject to an effective release of claims. The grant was approved by the Compensation Committee of the Board of Directors of the Company. Read SEC document |
| August 20, 2025 Filed Aug 22, 2025 20:15 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 237 | $19.95 | $4,728.15 |
DisclosureSEC source: 0001104659-25-081891 · tm2524111-2_4seq1.xml · nonDerivative · entry 1 Basso Stephen · CIK 0001815707 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,281 F1 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:15 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 237 | $18.78 | $4,450.86 |
DisclosureSEC source: 0001104659-25-051998 · tm2515701-6_4seq1.xml · nonDerivative · entry 2 Basso Stephen · CIK 0001815707 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,518 F2 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Read SEC document |
| May 15, 2025 Filed May 22, 2025 20:15 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 1,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-051998 · tm2515701-6_4seq1.xml · nonDerivative · entry 1 Basso Stephen · CIK 0001815707 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,755 F1 · shares: Includes 1,353 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on May 15, 2025. Read SEC document |
| February 24, 2025 Filed Mar 26, 2025 23:15 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 100,831 | $0.00 Strike: $18.08 | $0.00 |
DisclosureSEC source: 0000899140-25-000473 · form4.xml · derivative · entry 2 Basso Stephen · CIK 0001815707 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,730 Underlying: Common Stock · 100,831 shares Expires 2035-02-23 F2 · derivative.exercise_date: Twenty-five percent of the options vest on February 20, 2026 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date, with accelerated vesting (i) in the event of a "change in control" (as defined in the Issuer's 2012 Equity Incentive Plan) in which the options are not assumed or replaced, or (ii) in the event that the Reporting Person experiences an "involuntary termination" of employment within 24 months following a "change in control," subject to an effective release of claims. The grant was approved by the Compensation Committee of the Board of Directors of the Company. Read SEC document |
| February 24, 2025 Filed Mar 26, 2025 23:15 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 10,569 | $18.08 | $191,087.52 |
DisclosureSEC source: 0000899140-25-000473 · form4.xml · nonDerivative · entry 1 Basso Stephen · CIK 0001815707 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,402 F1 · shares: The Reporting Person was granted a time-vested restricted stock unit ("RSU"). Twenty-five percent of the shares subject to the RSU vest on February 20, 2026 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date, with accelerated vesting (i) in the event of a "change in control" (as defined in the Issuer's 2012 Equity Incentive Plan) in which the RSU is not assumed or replaced, or (ii) in the event that the Reporting Person experiences an "involuntary termination" of employment within 24 months following a "change in control," subject to an effective release of claims. The grant was approved by the Compensation Committee of the Board of Directors of the Company. Read SEC document |
| February 20, 2025 Filed Feb 24, 2025 22:26 UTC | Innoviva, Inc. INVA · Entity 4679 | Tax withholdingCommon Stock | 1,106 | $18.07 | $19,985.42 |
DisclosureSEC source: 0000899140-25-000360 · form4.xml · nonDerivative · entry 2 Basso Stephen · CIK 0001815707 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,833 F2 · shares: The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants. Read SEC document |
| November 15, 2024 Filed Feb 24, 2025 22:26 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 843 | $0.00 | $0.00 |
DisclosureSEC source: 0000899140-25-000360 · form4.xml · nonDerivative · entry 1 Basso Stephen · CIK 0001815707 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,939 F1 · shares: Includes 843 shares of common stock acquired under the Innoviva, Inc. Employee Stock Purchase Plan on November 15, 2024. Read SEC document |
| March 05, 2024 Filed Mar 8, 2024 00:04 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNon-statutory Stock Option · Derivative | 25,899 | $0.00 Strike: $14.88 | $0.00 |
DisclosureSEC source: 0001104659-24-032003 · tm248180-4_4seq1.xml · derivative · entry 2 Basso Stephen · CIK 0001815707 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,899 Underlying: Common Stock · 25,899 shares Expires 2034-03-05 F2 · derivative.exercise_date: 25% of the options will vest on February 20, 2025 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, subject to Mr. Basso's continuous service through the applicable vesting date, with accelerated vesting (i) in the event of a "change in control" (as defined in the Issuer's 2012 Equity Incentive Plan) in which the options are not assumed or replaced, or (ii) in the event that Mr. Basso experiences a termination of employment by the Innoviva, Inc. without "cause" or by Mr. Basso for "good reason" (each as defined in Mr. Basso's employment agreement) within 24 months following a "change in control," subject to an effective release of claims. Read SEC document |
| March 05, 2024 Filed Mar 8, 2024 00:04 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantCommon Stock | 12,096 | $14.88 | $179,988.48 |
DisclosureSEC source: 0001104659-24-032003 · tm248180-4_4seq1.xml · nonDerivative · entry 1 Basso Stephen · CIK 0001815707 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,096 F1 · shares: The Reporting Person was granted a one time-based restricted stock unit ("RSU"). Twenty-five percent of the shares subject to the RSU shall vest on February 20, 2025, 6.25% on May 20, 2025, and an additional 6.25% on the final day of each 3-month period thereafter, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The grant was approved by the Compensation Committee of the Board of Directors of the Company. Read SEC document |
| August 31, 2023 Filed Sep 1, 2023 00:12 UTC | Innoviva, Inc. INVA · Entity 4679 | GrantNonqualified Stock Option · Derivative | 150,000 | $0.00 Strike: $12.75 | $0.00 |
DisclosureSEC source: 0001104659-23-097374 · tm2325325-1_4seq1.xml · derivative · entry 1 Basso Stephen · CIK 0001815707 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-11-20 F1 · derivative.exercise_date: 25% of the options will vest on November 20, 2024 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, subject to Mr. Basso's continuous service through the applicable vesting date, with accelerated vesting (i) in the event of a "change in control" (as defined in the Issuer's 2012 Equity Incentive Plan) in which the options are not assumed or replaced, or (ii) in the event that Mr. Basso experiences a termination of employment by the Innoviva, Inc. without "cause" or by Mr. Basso for "good reason" (each as defined in Mr. Basso's employment agreement) within 12 months following a "change in control," subject to an effective release of claims. Read SEC document |
| March 24, 2021 Filed Mar 25, 2021 20:05 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock Option (right to buy) · Derivative | 13,000 | $0.00 Strike: $17.77 | $0.00 |
DisclosureSEC source: 0001209191-21-022980 · doc4.xml · derivative · entry 1 Basso Stephen · CIK 0001815707 · SVP Finance (PFO) 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2031-03-23 F1 · derivative.exercise_date: The option was granted on March 24, 2021. The shares underlying the option are scheduled to vest in equal monthly installments through March 24, 2023. Read SEC document |
| March 04, 2021 Filed Mar 17, 2021 21:56 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $19.78 | $0.00 |
DisclosureSEC source: 0001209191-21-021482 · doc4.xml · derivative · entry 1 Basso Stephen · CIK 0001815707 · SVP Finance (PFO) 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2031-03-03 F1 · derivative.exercise_date: The option was granted on March 4, 2021. The shares underlying the option are scheduled to vest in equal monthly installments from March 4, 2021 through March 4, 2025. Read SEC document |
| January 13, 2021 Filed Jan 14, 2021 21:15 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock Option (right to buy) · Derivative | 41,794 | $0.00 Strike: $2.77 | $0.00 |
DisclosureSEC source: 0001209191-21-003594 · doc4.xml · derivative · entry 1 Basso Stephen · CIK 0001815707 · SVP Finance (PFO) 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,794 Underlying: Common Stock · 41,794 shares Expires 2030-04-22 F1 · derivative.exercise_date: This option was granted on April 23, 2020, with vesting subject to the satisfaction of performance based vesting criteria. The performance based vesting criteria were satisfied on January 13, 2021 and the shares underlying the option vest in equal monthly installments from April 23, 2020 through April 23, 2024. Read SEC document |
| July 23, 2020 Filed Jul 24, 2020 20:42 UTC | Inozyme Pharma, Inc. INZY · Entity 77717 | GrantStock Option (right to buy) · Derivative | 27,433 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-20-020388 · doc4.xml · derivative · entry 1 Basso Stephen · CIK 0001815707 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,433 Underlying: Common Stock · 27,433 shares Expires 2030-07-22 F1 · derivative.exercise_date: The option was granted on July 23, 2020. The shares underlying the option are scheduled to vest in equal monthly installments from July 23, 2020 through July 23, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.